Difference between revisions of "Carmustine (BCNU)"
Jump to navigation
Jump to search
m |
m |
||
Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Patient drug information== | ==Patient drug information== | ||
Line 44: | Line 38: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
− | [[Category: | + | [[Category:Nitrosureas]] |
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
+ | [[Category:Central nervous system (CNS) cancer medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] |
Revision as of 19:45, 17 May 2014
General information
Class/mechanism: Nitrosourea, alkylates DNA and RNA, inhibits several key enzymatic processes by carbamoylation of amino acids in proteins.[1][2]
Route: IV
Extravasation: vesicant/irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Carmustine (BiCNU) patient drug information (Chemocare)[3]
- Carmustine (BiCNU) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 3/7/1977: Initial FDA approval
Also known as
Precise Name: Carmustine (RXCUI 2105)
Synonyms | |||||||
---|---|---|---|---|---|---|---|
BCNU | Becenun | BiCNU | bischloroethylnitrosourea | Carmubris | Carmustin Bcnu | Gliadel | Gliadel Wafer |
Leucerom | Nitrourean | Nitrumon |